STOCK TITAN

If You Invested in Bristol-Myers Squibb Co. (BMY)

Healthcare · Drug Manufacturers - General · NYSE
Looking for the current price? See the BMY quote & overview
$1,000 invested 1 Year Ago
$1,304
+30.4% price return
+36.2% with dividends reinvested
Bought on Nov 18, 2025 at $47.06 split-adjusted
$1,000 invested 5 Years Ago
$1,039
+3.9% price return 0.8% CAGR
+27.8% with dividends reinvested
Bought on Nov 18, 2021 at $59.04 split-adjusted

What $1,000 or $10,000 in BMY Would Be Worth Now

Real historical value by amount invested and how long ago
If you invested 1 year ago 5 years ago 10 years ago Since Nov 19, 2015
$1,000 $1,304 +30% $1,039 +4% $1,081 +8% $916 -8%
$10,000 $13,037 +30% $10,391 +4% $10,809 +8% $9,165 -8%

Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-17. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.

Custom Calculation

Choose your own date and amount for BMY

$1,000 Investment Over Time

BMY vs S&P 500

Year-by-Year Returns

BMY annual performance
Year Start Price End Price Annual Return Cumulative
2015Nov 19 to Dec 31 $66.94 $68.79 +2.8% +2.8%
2016 $68.79 $58.44 -15.0% -12.7%
2017 $58.44 $61.28 +4.9% -8.5%
2018 $61.28 $51.98 -15.2% -22.3%
2019 $51.98 $64.19 +23.5% -4.1%
2020 $64.19 $62.03 -3.4% -7.3%
2021 $62.03 $62.35 +0.5% -6.9%
2022 $62.35 $71.95 +15.4% +7.5%
2023 $71.95 $51.31 -28.7% -23.3%
2024 $51.31 $56.56 +10.2% -15.5%
2025 $56.56 $53.94 -4.6% -19.4%
2026Dec 31, 2025 to Nov 17 $53.94 $61.35 +13.7% -8.4%

About Bristol-Myers Squibb Co.

Healthcare · NYSE

Bristol-Myers Squibb Company (NYSE: BMY) is a global biopharmaceutical company in the pharmaceutical preparation manufacturing industry. According to company disclosures, its mission is to discover, develop and deliver medicines that help patients prevail over serious diseases. The company’s common stock and multiple series of senior notes are listed on the New York Stock Exchange, reflecting an established presence in public capital markets.

Bristol Myers Squibb focuses on therapies for serious conditions across several therapeutic areas. Company communications describe a strong emphasis on cardiovascular disease, oncology and immune-related disorders. In particular, the firm highlights immuno-oncology as a key area of drug development, with immuno-oncology medicines positioned as important treatment options in multiple cancer types. The company also notes that a significant portion of its sales are generated in the United States.

Core business and therapeutic focus

The company states that it discovers, develops and markets drugs for cardiovascular conditions, cancer and immune disorders. Within cardiovascular disease, Bristol Myers Squibb co-promotes Eliquis (apixaban), an oral anticoagulant used to reduce the risk of stroke and blood clots in adults with certain types of atrial fibrillation, to help prevent and treat deep vein thrombosis and pulmonary embolism in adults, and to treat and reduce the risk of recurrent venous thromboembolism in children from birth and older after initial anticoagulant treatment. Eliquis is described as a widely prescribed oral blood thinner in the United States.

In oncology and hematology, Bristol Myers Squibb has built a portfolio that includes immuno-oncology agents and cell therapies. Opdivo (nivolumab), a programmed death-1 (PD-1) immune checkpoint inhibitor, is described as an important treatment option across multiple cancers, with regulatory approvals in numerous tumor types such as melanoma, non-small cell lung cancer, classical Hodgkin lymphoma, renal cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal and gastroesophageal cancers and others, based on specific indications outlined in prescribing information. The company also markets the Opdivo plus Yervoy (ipilimumab) combination regimen in several settings.

In cell therapy, Bristol Myers Squibb develops and commercializes Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy. Breyanzi is indicated in the United States for adult patients with certain relapsed or refractory large B-cell lymphomas after specified prior therapies, as well as for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma after defined prior lines of systemic therapy. Company materials emphasize that Breyanzi is administered as a one-time infusion following a multi-step treatment process that includes T cell collection, genetic modification, lymphodepletion and post-infusion monitoring.

Pipeline and research areas

Bristol Myers Squibb reports active research and development programs across hematology, oncology, cardiovascular disease and neuroscience. In hematology and lymphoma, the company is advancing targeted protein degradation agents such as the investigational CELMoD agent golcadomide and the BCL6 ligand-directed degrader BMS-986458, with clinical data presented in aggressive B-cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma. These programs are being studied in combination with established regimens such as R-CHOP and rituximab, as well as in monotherapy settings in relapsed or refractory non-Hodgkin lymphoma.

In cardiology, Bristol Myers Squibb develops Camzyos (mavacamten), described as a selective, reversible, allosteric inhibitor of cardiac myosin that targets the pathophysiology of hypertrophic cardiomyopathy by reducing left ventricular outflow tract obstruction and improving cardiac filling pressures in obstructive hypertrophic cardiomyopathy (oHCM). Camzyos is indicated in the United States for adults with symptomatic New York Heart Association class II–III oHCM and has been studied extensively in clinical trials. The company recently announced positive topline results from the Phase 3 SCOUT-HCM trial, the first randomized, placebo-controlled study of a cardiac myosin inhibitor in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.

In neuroscience, Bristol Myers Squibb is advancing Cobenfy, which is described as a treatment for schizophrenia in adults and is being evaluated in the ADEPT clinical program for psychosis associated with Alzheimer’s disease. The ADEPT-2 Phase 3 trial is a multicenter, randomized, double-blind, placebo-controlled study assessing safety and efficacy in psychosis associated with Alzheimer’s disease dementia, with endpoints focused on neuropsychiatric symptom scales and clinical global impression measures.

Collaborations and external innovation

The company supplements its internal research with collaborations. For example, Bristol Myers Squibb has a multi-target collaboration with Terray Therapeutics that uses Terray’s EMMI platform, which combines high-throughput chemical experimentation with AI-driven analysis to accelerate small molecule discovery. This collaboration is described as aiming to identify and optimize novel molecules for difficult-to-drug targets in areas of significant unmet medical need.

Regulatory and market footprint

Bristol Myers Squibb’s products are approved in multiple countries and regions, as reflected in company statements. Camzyos is noted as being approved by regulatory bodies in more than 50 countries and regions across five continents for adult symptomatic obstructive hypertrophic cardiomyopathy, and Opdivo is described as approved in more than 65 countries, including the United States, the European Union, Japan and China. Breyanzi has approvals in the United States and several other jurisdictions, including Japan, the European Union, Switzerland, Israel, the United Kingdom and Canada for specified lymphoma indications.

The company’s securities filings confirm that Bristol-Myers Squibb Company is the parent guarantor of multiple series of euro-denominated senior notes issued by a wholly owned Irish subsidiary, BMS Ireland Capital Funding Designated Activity Company. These notes, along with various U.S.-listed notes and Celgene contingent value rights, are registered on the New York Stock Exchange, underscoring the firm’s use of global debt markets to support its operations and capital allocation activities.

Capital allocation and shareholder returns

Bristol Myers Squibb’s board of directors declares regular dividends on its common and preferred stock. In a recent announcement, the company reported a quarterly dividend on its common stock and noted that it has paid dividends for many consecutive years, with a long history of annual increases. The company also conducts tender offers and other transactions involving its outstanding notes, and issues new debt securities under an indenture structure to manage its capital structure and fund corporate purposes, including repurchases, repayments or redemptions of existing notes.

Risk management and safety programs

Given the nature of its therapies, Bristol Myers Squibb describes extensive safety and risk management programs. For Camzyos, the company highlights a boxed warning for risk of heart failure due to systolic dysfunction and notes that the medicine is available only through the CAMZYOS Risk Evaluation and Mitigation Strategy (REMS) Program, which requires certification of prescribers and pharmacies, patient enrollment and ongoing monitoring. For Eliquis, Opdivo and Breyanzi, the company provides detailed important safety information, including boxed warnings for bleeding risk with Eliquis and for cytokine release syndrome, neurologic toxicities and secondary hematological malignancies with Breyanzi. These disclosures outline monitoring requirements, contraindications, drug interactions and management approaches for adverse events.

Geographic base and corporate identity

Regulatory filings list Bristol-Myers Squibb Company’s principal offices in Princeton, New Jersey. The company identifies itself as a global biopharmaceutical enterprise and emphasizes a mission of transforming patients’ lives through science. Public communications reiterate a focus on bold science, serious diseases and collaboration with healthcare providers and policymakers, including agreements with the U.S. government to improve affordability and access to certain medicines such as Eliquis for Medicaid beneficiaries.

Market Cap
$125.4B
Current Price
$61.35
EPS (FY2025)
$3.46
Revenue (FY2025)
$48.2B
Net Margin (FY2025)
14.6%
View full BMY overview

Frequently Asked Questions

Bristol-Myers Squibb Co. investment returns

How much would $1,000 invested in Bristol-Myers Squibb Co. be worth today?

If you invested $1,000 in Bristol-Myers Squibb Co. (BMY) 10 years ago on 2016-11-18, your investment would be worth $1,081 as of 2026-11-17, a +8.1% price return without dividends, growing at a compounded rate of 0.8% per year (CAGR).

Has Bristol-Myers Squibb Co. outperformed the S&P 500?

Over the past 10 years, BMY returned +8.1% compared to +235.2% for the S&P 500, underperforming the benchmark by 227.1 percentage points.

What is Bristol-Myers Squibb Co.'s average annual return?

The compound annual growth rate (CAGR) of BMY’s share price over the past 10 years is 0.8%, without dividends. Individual years vary a great deal, and BMY’s best recent full year was 2019 (+23.5%) while the worst was 2023 (-28.7%).

For informational and educational purposes only, not investment advice.